BR112022009217A2 - Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos - Google Patents
Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmosInfo
- Publication number
- BR112022009217A2 BR112022009217A2 BR112022009217A BR112022009217A BR112022009217A2 BR 112022009217 A2 BR112022009217 A2 BR 112022009217A2 BR 112022009217 A BR112022009217 A BR 112022009217A BR 112022009217 A BR112022009217 A BR 112022009217A BR 112022009217 A2 BR112022009217 A2 BR 112022009217A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- polypeptides
- xten
- compositions
- producing
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
Abstract
POLIPEPTÍDEOS XTEN COM CÓDIGO DE BARRAS E COMPOSIÇÕES DESTES, E MÉTODOS PARA PRODUZIR E USAR OS MESMOS. A presente invenção refere-se a polipeptídeos que compreendem um polipeptídeo recombinante estendido (XTEN) composto por uma pluralidade de motivos de sequência sobrepostos e um ou mais fragmentos de código de barras liberáveis mediante digestão de protease e detectáveis de todos os outros fragmentos proteoliticamente liberáveis. Certas modalidades desses polipeptídeos compreendem ainda um polipeptídeo biologicamente ativo, em que modalidades vantajosas do mesmo compreendem um segmento liberável capaz de clivagem proteolítica que cliva a ligação entre o polipeptídeo XTEN e o polipeptídeo biologicamente ativo. São divulgados também métodos de fabricação e métodos de uso dos referidos polipeptídeos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934980P | 2019-11-13 | 2019-11-13 | |
PCT/US2020/060378 WO2021097186A1 (en) | 2019-11-13 | 2020-11-13 | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009217A2 true BR112022009217A2 (pt) | 2022-08-02 |
Family
ID=73740585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009217A BR112022009217A2 (pt) | 2019-11-13 | 2020-11-13 | Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230287040A1 (pt) |
EP (1) | EP4058466A1 (pt) |
JP (1) | JP2023501478A (pt) |
KR (1) | KR20220131221A (pt) |
CN (1) | CN115175920A (pt) |
AU (1) | AU2020382621A1 (pt) |
BR (1) | BR112022009217A2 (pt) |
CA (1) | CA3157605A1 (pt) |
CO (1) | CO2022008004A2 (pt) |
IL (1) | IL292863A (pt) |
MX (1) | MX2022005676A (pt) |
WO (1) | WO2021097186A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3990497A4 (en) * | 2019-06-26 | 2023-07-19 | Amunix Pharmaceuticals, Inc. | CD3 ANTIGEN-BINDING FRAGMENTS AND COMPOSITIONS COMPRISING THEM |
IL298815A (en) * | 2020-06-25 | 2023-02-01 | Amunix Pharmaceuticals Inc | Bispecific compositions targeting HER-2 and methods for their preparation and use |
WO2023092099A1 (en) * | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0134631B1 (en) | 1983-06-15 | 1991-04-03 | Celltech Limited | Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents |
DK27885A (da) | 1985-01-22 | 1986-07-23 | Novo Industri As | Fremstilling af peptider |
AU590006B2 (en) | 1985-09-12 | 1989-10-26 | Scios Nova Inc. | Recombinant fibroblast growth factors |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
CA1339210C (en) | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5114923A (en) | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5631230A (en) | 1989-09-21 | 1997-05-20 | Arizona Technology Development Corporation | Receptor selective analogues of cholecystokinin-8 |
US5364840A (en) | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
EP0548267A4 (en) | 1990-09-04 | 1994-11-23 | Salk Inst Biotech Ind | Production of insulin-like growth factor-1 in methylotrophic yeast cells |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
EP0692971A4 (en) | 1993-03-29 | 1997-11-12 | Univ Cincinnati | PEPTIDE YY ANALOGS AND USES THEREOF |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
US6214797B1 (en) | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
JPH11512087A (ja) | 1995-08-18 | 1999-10-19 | アメリカ合衆国 | ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割 |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
US20020042367A1 (en) | 1997-11-25 | 2002-04-11 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
AU772069B2 (en) * | 1999-03-23 | 2004-04-08 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Protein isolation and analysis |
EP1197496B8 (en) | 1999-07-23 | 2007-10-03 | Kenji Kangawa | Novel peptides |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
PL204285B1 (pl) | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
JP4237375B2 (ja) | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US7419949B2 (en) | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
WO2004048547A2 (en) | 2002-11-26 | 2004-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US20050214859A1 (en) | 2003-03-03 | 2005-09-29 | Dyax Corp. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
EP1753783B1 (en) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
US20100209437A1 (en) | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
CA2989778C (en) | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
WO2010037835A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN116925238A (zh) | 2009-02-03 | 2023-10-24 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
DK2440228T3 (en) | 2009-06-08 | 2018-12-17 | Amunix Operating Inc | Glucose regulating polypeptides and methods for their preparation and use |
MX354555B (es) | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
PT2882450T (pt) | 2012-07-11 | 2020-02-19 | Bioverativ Therapeutics Inc | Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP3218390A4 (en) * | 2014-11-11 | 2018-11-21 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
US9601471B2 (en) | 2015-04-23 | 2017-03-21 | Apple Inc. | Three layer stack structure |
JP6558679B2 (ja) | 2015-04-24 | 2019-08-14 | パナソニックIpマネジメント株式会社 | 点灯装置、照明装置及び照明器具 |
US11339434B2 (en) * | 2016-07-29 | 2022-05-24 | The Regents Of The University Of California | Methods for determining gene functions |
EP3728326A4 (en) * | 2017-12-21 | 2021-12-15 | Amunix Pharmaceuticals, Inc. | RELEASE SEGMENTS AND LIAISON COMPOSITIONS INCLUDING THEM |
-
2020
- 2020-11-13 AU AU2020382621A patent/AU2020382621A1/en active Pending
- 2020-11-13 US US17/776,478 patent/US20230287040A1/en active Pending
- 2020-11-13 IL IL292863A patent/IL292863A/en unknown
- 2020-11-13 BR BR112022009217A patent/BR112022009217A2/pt not_active Application Discontinuation
- 2020-11-13 WO PCT/US2020/060378 patent/WO2021097186A1/en active Application Filing
- 2020-11-13 CN CN202080090841.XA patent/CN115175920A/zh active Pending
- 2020-11-13 JP JP2022526756A patent/JP2023501478A/ja active Pending
- 2020-11-13 MX MX2022005676A patent/MX2022005676A/es unknown
- 2020-11-13 CA CA3157605A patent/CA3157605A1/en active Pending
- 2020-11-13 KR KR1020227019674A patent/KR20220131221A/ko unknown
- 2020-11-13 EP EP20820695.3A patent/EP4058466A1/en active Pending
-
2022
- 2022-06-06 CO CONC2022/0008004A patent/CO2022008004A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4058466A1 (en) | 2022-09-21 |
CA3157605A1 (en) | 2021-05-20 |
WO2021097186A1 (en) | 2021-05-20 |
MX2022005676A (es) | 2022-10-27 |
CN115175920A (zh) | 2022-10-11 |
CO2022008004A2 (es) | 2022-10-21 |
JP2023501478A (ja) | 2023-01-18 |
IL292863A (en) | 2022-07-01 |
KR20220131221A (ko) | 2022-09-27 |
AU2020382621A1 (en) | 2022-06-02 |
US20230287040A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022009217A2 (pt) | Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos | |
AR109680A1 (es) | Proteínas recombinantes y sus usos | |
CO2022016595A2 (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
ATE350470T1 (de) | Durch thrombin spaltbare chimäre proteine | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
AR081454A1 (es) | Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9 (proproteina convertasa subtilisina kexina 9) | |
BRPI0518559A2 (pt) | motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos | |
PE20110310A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas | |
BR112017018491A2 (pt) | hidrolisados de proteína à base de leite e composições produzidas a partir dos mesmos | |
EA202190889A1 (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации | |
ATE449790T1 (de) | Rekombinante gelatinepartikel für die zelladhäsion | |
DE60139072D1 (de) | Masp-2, ein komplement fixierendes enzym, und dessen verwendungen | |
BR112021023218A2 (pt) | Polipeptídeos sintase de canabinoide otimizados | |
BR112021017827A2 (pt) | Proteínas de fusão, bactérias recombinantes e fragmentos de exosporium para o controle de pestes e saúde das plantas | |
CL2021000883A1 (es) | Composiciones de polipéptidos estabilizados con enlace disulfuro y métodos de uso | |
MX2020005670A (es) | Variantes de expresión de cdkl5 y proteínas de fusión de cdkl5. | |
BR112021022755A2 (pt) | Sequências de alvos para plataforma de visualização de endosporos à base de paenibacillus | |
DE60118935D1 (de) | Dna & protein bindende miniatur proteine | |
BR112022015325A2 (pt) | Sistemas e métodos para alta produção de microganismos recombinantes e uso dos mesmos | |
BR112022004797A2 (pt) | Polipeptídeos otimizados de ácido tetra-hidrocanabinólico (thca) sintase | |
Sitprija et al. | Proteomics and immunocharacterization of Asian mountain pit viper (Ovophis monticola) venom | |
MX2020010030A (es) | Metodos y composiciones que comprenden proteina d tensoactiva (sp-d). | |
MX2022004410A (es) | Polipeptidos recombinantes para localizacion celular regulable. | |
CO2022004535A2 (es) | Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes | |
ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |